|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.22 HKD | -8.76% |
|
-4.48% | +6.44% |
| 07-16 | Genscript Associate Reports $657 Million in Carvykti Sales Under License Agreement | MT |
| 06-15 | Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma | MT |
Evolution of the Average Target: Genscript Biotech Corporation
Evolution of the Target Price: Genscript Biotech Corporation
Changes in Analyst Recommendations: Genscript Biotech Corporation
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +33.75% | |||||
| +7.7% | |||||
| +32.95% | |||||
| +12.48% | |||||
| +46% | |||||
| +15.74% | |||||
| -12.16% | |||||
| +1.07% | |||||
| +6.95% | |||||
| +16.24% | |||||
| Average | +16.07% | |||||
| Weighted average by Cap. | +17.22% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Jefferies & Co. |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1548 Stock
- Consensus Genscript Biotech Corporation
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition